NMDA Reduces Tau Phosphorylation in Rat Hippocampal Slices by Targeting NR2A Receptors, GSK3β, and PKC Activities
Figure 6
NMDA-induced changes in Tau phosphorylation require PKC activation. (a) Phosphorylated Tau levels at Ser199-202 were estimated by Western blotting of cell extracts obtained from hippocampal slices treated with 10 μM NMDA for 1 hour alone or in combination with the Akt/PKB inhibitor 10-DEBC hydrochloride (10-DEBC; 2.5 μM) and the PI3K inhibitor LY294002 (10 μM). The data are expressed relative to total Tau (i.e., Tau-5) levels. (b) As in (a), except that the cdk5 inhibitor Roscovitine (Rosco; 10 μM) and the global PKC inhibitor Chelerythrine chloride (Chele; 1 μM) were employed. The data are expressed as percentages of control values and are means ± S.E.M. of 3 measurements per cell extract obtained from 6 different rats. For statistical analysis, one-way ANOVA was followed by Newman-Keuls post hoc test. *, **, ***, drug-treated versus control.
